ADCs & Engineered Antibodies Conferences
The ADC renaissance is here to stay with increased innovation, investments, and collaborations leading to more approvals of safe and effective ADCs on the market.
With positive clinical readouts continuing, capitalize on novel conjugates, payloads, and targets, and optimize clinical trial and manufacturing best practice to develop the next generation of ADCs for oncology patients in need.
0
Sponsors
0
Speakers
0
Attendees